ProRx LLC, Exton, PA

Is ProRx LLC an FDA-registered 503B outsourcing facility?

Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names ProRx LLC in Exton, PA, first registered Apr 27, 2022 and most recently registered Feb 20, 2026. FDA lists its last inspection as Sep 19, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Warning Letter Issued 4/7/2026”.

FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.

Location on FDA’s list
Exton, PA
Initial registration
Apr 27, 2022
Most recent registration
Feb 20, 2026
Last inspection
Sep 19, 2025
Form 483 issued at last inspection
Yes
Recall after last inspection
No
Action on last inspection
Warning Letter Issued 4/7/2026
Intends to compound sterile drugs from bulk substances
Yes

FDA inspections and actions on record

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as ProRX LLC, Exton, PA, a 503B facility, with 4 listed actions, including 2 Form 483s and 2 warning letters (2024 to 2026).

Document
Apr 7, 2026Warning letterWarning Letter Issued 04/07/2026fda.gov
Sep 19, 2025Form 483483 Issued 09/19/2025fda.gov
Mar 4, 2025Warning letterAmended Warning Letter Issued 03/04/2025FDA copy (archived)
Aug 2, 2024Form 483483 Issued 08/02/2024FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists ProRx LLC, Exton, PA (FEI number 3022250654), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Sep 19, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30222506541278378
Aug 2, 2024Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30222506541245419

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 13 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jul 15, 2024 to Aug 2, 2024: 13 observations

Firm on the cover
ProRx LLC, 619 Jeffers Cir, Exton, PA 19341-2540
FEI number
3022250654
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
US Customhouse Rrn900 200 Chestnut St Philadelphia, PA 19106
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically,

A) On 07/25/2024, during the production of Semaglutide 2.5mg/ml, Lot# <Redacted B4> Exp. 01/24/2025, your firm's operator was observed filing sterile drug product in a manner that directly blocked first pass air over uncapped and filled vials of Semaglutide 2.5 mg/ml. Additionally, your Pharmacist-in-Charge (PIC), was observed rapidly prodding a pile of sterilized rubber caps with forceps, in an attempt to dislodge them, inside of the ISO 5 Biosafety Cabinet (BSC) Hood-I , Asset #A-051, near uncapped filled vials of Semaglutide 2.5 mg/ml.

B) On 07/16/2024, your firm's PIC was observed exposing their bare hands in the ISO 5 BCS hood to don sterile gloves after the BSC was cleaned and prior to manufacturing sterile drug production, Vancomycin 25mg/ml, Lot: <Redacted B4>, Exp.: 08/02/2024.

C) On 07/25/2024, your firm's PIC was observed bending down on the floor, on their hands and knees inside of the ISO 7 Anteroom. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Specifically, your firm's media fill program is inadequate as it does not provide an assurance that your staff can manufacture drug product under aseptic conditions. The following deficiencies were identified:

A) Media fills are not performed in accordance with a written procedure, ProSOP-B052, SOP For Media Fill.

B) Your media fill studies fail to ensure that all simulated aseptic manufacturing operations are represented to include the worst-case scenario (number of vials filled/ batch size/ volume/ time/ interventions) in order to assess the potential for batch contamination. There have been <Redacted B4> media fills studies performed at your site to date (2/28/2023, 4/2/2023, 4/2/2023, 4/16/2023, 1/12/2024, and 4/11/2024). ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

A) Your firm failed to capture any types of environmental and personnel monitoring during all sterile drug production performed at your facility. There have been approximately <Redacted B4> batches of sterile drug products produced onsite since August 2023 without environmental or personnel monitoring performed during production.

(i) Environmental monitoring, which you only perform <Redacted B4> is not performed under dynamic conditions.

(ii) Surface and viable air monitoring plates are only incubated for a total of <Redacted B4>. The existing incubation temperature and duration for media used in environmental monitoring does not account for the detection of fungi (i.e. yeast and molds). Your firm does not have any scientific justification to ensure that the incubation period used to incubate your viable <Redacted B4> plates is adequate to capture objectionable organisms.

(iii) There has not been any personnel monitoring conducted and documented for your personnel that operate inside ofthe ISO 5 BSC environment to produce sterile drug product. ...

Read the full 483 (PDF on fda.gov)

Observation 4

The responsibilities and procedures applicable to the quality control unit are not.

Specifically,

A) Your firm has not implemented CGMP systems with quality oversight, nor do you have personnel with CGMP knowledge to oversee these systems. The following deficiencies were observed, indicating inadequate oversight during quality control operations, manufacturing operations, and release procedures for drug products. The following systeinic deficiencies were noted:

• Your firm fails to ensure meta data generated is backed up on computer systems.

• Your firm fails to assess, document, mitigate risk for, track, and approve changes that might impact drug product quality, i.e. changing API vendors, batch sizes, formulation changes, and fill volumes.

• Your firm fails to have processes and procedures for change control, recall, stability studies, process validation, supplier verification, preventative maintenance, equipment validation (IP/OP/QP), etc. ...

Read the full 483 (PDF on fda.gov)

Observation 5

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

A) Your firm's media fill performed on 04/2/2023, had one turbid vial out of <Redacted B4> filled vials filled. Your firm's quality unit did not perform an investigation into the root cause, nor did you make an attempt identify the organism(s) in the turbid vial. The media fill performed on 04/02/2023 was not classified as a sterility failure; however, another media fill performed on 04/16/2023 was conducted due to the turbid vial. Incubated vials from the media fill performed on 04/16/2023 were only observed on day 7 for turbidity and were not observed for turbidity after <Redacted B4> of incubation. Your firm accepted the results of the media fill and failed to document results of your incubated vials for <Redacted B4> as required by SOP-052, Media Fills. There is no justification for failing to conduct an investigation and implement corrective and preventive actions (CAPA) related to the failed media fill. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Clothing of personnel engaged in the manufacturing, processing, packing and holding of drug products is not appropriate for the duties they perform.

Specifically,

A) On 07/16/2024 and 07/25/2024, your operators were observed donning non-sterile, disposable coats over their street clothing, and wearing disposable shoe covers to enter the ISO 7 Buffer room to aseptically fill sterile drug products, without using sterile sleeves inside of the ISO 5 BSC environment, i.e. Vancomycin 24mg/ml, Lot <Redacted B4> Exp: 08/02/2024 and Semaglutide 2.5mg/ml, Lot <Redacted B4> Exp: 01 2472025.

e

B) On 07/16/2024 and 07/25/2024, your operators were observed working in the ISO 5 BSC and ISO 7 Buffer room with inadequate gowning that exposed the forehead, neck, and eyes. Furthermore, disposable non-sterile laboratory coats and non-sterile cloth booties are laundered by staff at a local establishment and subsequently used again inside of the cleanroom areas.

C) There is no gowning qualification program at your facility.

Observation 7

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically, your firm has not performed a disinfectant study using <Redacted B4> solution, nor do you follow the manufacturer's direction for disinfection, which indicates that a wet contact time of <Redacted B4> is required to achieve disinfection efficacy when using sterile <Redacted B4> in a Cleanroom environments, ISO 5 and ISO 7. On 07/25/2024, we observed your firm only allow a wet contact time of five minutes before initiating the process to perform aseptic operations. Your firm is not ensuring that contact time are met to reach disinfection efficacy when <Redacted B4> items into the cleanroom area. Additionally, the non-pharmaceutical grade <Redacted B4> used as a <Redacted B4> sporicidal agent is only <Redacted B4> to clean the ISO 5 BSC, and the walls and floors of the ISO 7 Buffer Room and ISO 7 Anteroom. This strength as a sporicidal cleaning agent in the aseptic processing area is not supported by any scientific justification.

Observation 8

Buildings used in the manufacture, processing, packing or holding of drug products are not free of infestation by rodents, birds insects, and other vermin.

Specifically, your firm does not have an established pest control program. On 07/25/2024, a flying insect was observed on the walls and ceilings of the ISO 7 Anteroom and on the door inside of the ISO 7 Buffer Room, approximately 10 feet from the ISO 5 Biosafety Cabinet hood used for sterile drug processing. Additionally, there were approximately 4 crawling insects found in the perimeter area of your cleanroom that houses the HVAC system.

Observation 9

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance.

Specifically, your firm failed to perform protocol driven equipment qualification studies for the following equipment:

•< Redacted B4> A-027, used for sterilizing materials to be used in the cleanroom.

•<Redacted B4> A-025, used for diying the materials that exit the <Redacted B4> after the sterilization process;

• <Redacted B4> Incubator, A-028, used for incubating environmental monitoring samples;

•<Redacted B4> pumps, A-091 for <Redacted B4> operation and A-077 for filling operation, used for transfening various liquids;

• Refrigerator/ Freezer Units, A-030 and A-095, used for the storage of quarantined drug products prior to QA approval and A-100, which is the refrigerator for finished drug product prior to shipping;

•<Redacted B4> Biosafety Cabinet, A-051, which functions as an ISO 5 classified area for preparation of sterile drug products.

• HVAC, used to supply the cleanroom with adequate temperature and humidity,

•<Redacted B4> system, used on the HPLC and for cleaning in the cleanroom.

Observation 10

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, your firm does not have a written stability program that supports the expiration of your sterile and non-sterile drug products. Your firm extended the beyond-use-dates (BUD) for Semaglutide and Tirzepatide from a 30-day BUD to a 6-months with no supporting stability studies or documented scientifically sound rationale.

Observation 11

Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without performing at least one specific identity test on each component and establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.

Specifically,

A) Your firm has never formally qualified any of the API suppliers you use in the production of drug products. Your firm has no SOP for formally qualifying API suppliers. The following batches of Tirzepatide <Redacted B4> Expiry 12/09/2024, and <Redacted B4> Expiry 11/21/2024, were made with the active ingredient Tirzepatide which was obtained by an unqualified external API supplier. Additionally, your firm imported and used Semaglutide API, for production of sterile drug products from a vendor that had not been qualified.

B) Your firm does not perform identification testing for all incoming lots of APis used in non­sterile and sterile drug products.

Observation 12

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(l 0)(A) of the Federal Food, Drug and Cosmetic Act (FD&C Act).

Specifically,

A) The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(l 0)(A). The following information is not found on your drug product labels:

a. The statement "This is a compounded drug ";

b. The full address of the outsourcing facility;

c. The dosage form;

d. The statement "Office Use Only" for drugs dispensed or distributed other than pursuant to a prescription for an individual identified patient;

to a prescription for an individual identified patient;

e. A list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient. Examples of your drug product labels that do not contain this information:

• Semaglutide 5 mg/2 mL (2.5 mg/mL) 2 mL Multiple Dose Vial

• Tirzepetide 60 mg/3mL (20gm/mL) 3mL Multiple Dose Vial

B) The containers of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(B). ...

Read the full 483 (PDF on fda.gov)

Observation 13

Your outsourcing facility did not submit a report to FDA upon initial registration as an outsourcing facility identifying the drugs compounded during the previous six month period.

Specifically, your outsourcing facility did not submit required products reports upon initial registration of your facility on April 27, 2022 in June 2022 and December 2022.

Linked 483s whose text is not shown

GLP-1 records in this index

The same legal name appears in 2 GLP-1 warning letters and 14 GLP-1 recall reports in this index. See the ProRx LLC record page.

Later letters FDA listsLetter
Apr 7, 2026Compounding Pharmacy/Adulterated Drug ProductsSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov
Mar 4, 2025Compounding Pharmacy/Adulterated Drug ProductsSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

Record
Oct 15, 2025Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 841...Lack of Assurance of SterilityClass IIOngoingD-0115-2026
Oct 15, 2025Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84...Lack of Assurance of SterilityClass IIOngoingD-0116-2026
Oct 15, 2025Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 8413...Lack of Assurance of SterilityClass IIOngoingD-0118-2026
Oct 15, 2025Semaglutide Injection, 8mg/3.2mL (2.5 mg/mL), 3.2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84...Lack of Assurance of SterilityClass IIOngoingD-0117-2026
Oct 15, 2025Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139...Lack of Assurance of SterilityClass IIOngoingD-0114-2026
Oct 15, 2025Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 8413...Lack of Assurance of SterilityClass IIOngoingD-0119-2026
Oct 15, 2025Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139...Lack of Assurance of SterilityClass IIOngoingD-0120-2026
Aug 22, 2024Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx, 267-565-7008, NDC 84139-225-01Lack of Assurance of SterilityClass IIOngoingD-0650-2024
Aug 22, 2024Semaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mL, 2 mL Multiple Dose Vial, Compounded Rx Product, ProRX 267-565-7008, NDC 84139-225-02Lack of Assurance of SterilityClass IIOngoingD-0654-2024
Aug 22, 2024SEMAGLUTIDE 5mg/2mL (2.5mg/mL), Rx Only 2 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-01Lack of Assurance of SterilityClass IIOngoingD-0652-2024
Aug 22, 2024SEMAGLUTIDE 10mg/4mL (2.5mg/mL), 4 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-04Lack of Assurance of SterilityClass IIOngoingD-0653-2024
Aug 22, 2024Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01Lack of Assurance of SterilityClass IIOngoingD-0651-2024
Aug 22, 2024TIRZEPATIDE 60 mg/3mL (20/mg/mL), Rx Only, 3mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-02Lack of Assurance of SterilityClass IIOngoingD-0656-2024
Aug 22, 2024TIRZEPATIDE 20 mg/2mL (10/mg/mL), Rx Only, 2mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-01Lack of Assurance of SterilityClass IIOngoingD-0655-2024

The ProRx LLC pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.